v3.26.1
SEGMENT INFORMATION - Schedule of Income Before Income Taxes Regarding the Company's Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Financial information regarding the Company's reportable segments        
Net Sales $ 1,026,508 $ 966,009 $ 2,009,376 $ 1,853,314
Cost of Sales (exclusive of depreciation and amortization): 660,991 598,994 1,291,950 1,149,885
Selling, Research & Development and Administrative: 157,735 151,139 325,337 306,416
Acquisition-related costs (38) (344) (228) (344)
Restructuring Initiatives (1,419) (1,579) (2,505) (3,621)
Net unrealized investment gain (loss) 849 2,102 (237) 1,006
Other special items (4,077) 0 (7,804) 0
Depreciation and amortization (79,641) (69,904) (155,366) (135,551)
Interest Expense (16,001) (10,850) (32,943) (22,201)
Interest Income 2,787 1,880 6,429 4,694
Income before Income Taxes 115,047 139,714 208,818 245,729
Pharma        
Financial information regarding the Company's reportable segments        
Net Sales 458,167 442,589 896,727 852,056
Beauty        
Financial information regarding the Company's reportable segments        
Net Sales 367,454 334,849 731,089 640,556
Closures        
Financial information regarding the Company's reportable segments        
Net Sales 200,887 188,571 381,560 360,702
Operating Segment        
Financial information regarding the Company's reportable segments        
Net Sales 1,038,307 975,346 2,031,565 1,871,265
Adjusted EBITDA 228,496 235,787 438,858 442,635
Depreciation and amortization (78,537) (69,091) (153,127) (133,876)
Operating Segment | Pharma        
Financial information regarding the Company's reportable segments        
Net Sales 458,321 442,817 897,229 852,514
Cost of Sales (exclusive of depreciation and amortization): 243,537 224,879 472,073 430,016
Selling, Research & Development and Administrative: 65,145 60,703 133,261 123,186
Other Segment Items: (4,420) 176 (8,735) (427)
Adjusted EBITDA 153,905 156,831 300,128 299,281
Restructuring Initiatives 66 (68) 61 (258)
Depreciation and amortization (39,260) (34,169) (74,903) (65,317)
Operating Segment | Beauty        
Financial information regarding the Company's reportable segments        
Net Sales 377,426 342,251 749,584 654,552
Cost of Sales (exclusive of depreciation and amortization): 270,862 241,378 542,350 465,426
Selling, Research & Development and Administrative: 52,846 48,738 105,476 95,150
Other Segment Items: (996) (2,340) (1,961) (4,231)
Adjusted EBITDA 44,742 47,073 85,224 84,211
Restructuring Initiatives (1,417) (626) (2,718) (1,021)
Depreciation and amortization (24,750) (21,475) (49,473) (41,537)
Operating Segment | Closures        
Financial information regarding the Company's reportable segments        
Net Sales 202,560 190,278 384,752 364,199
Cost of Sales (exclusive of depreciation and amortization): 146,864 133,362 278,747 255,753
Selling, Research & Development and Administrative: 24,707 23,858 49,652 46,870
Other Segment Items: (533) (532) (345) (1,064)
Adjusted EBITDA 29,849 31,883 53,506 59,143
Restructuring Initiatives (87) (890) (336) (2,242)
Depreciation and amortization (14,527) (13,447) (28,751) (27,022)
Intersegment        
Financial information regarding the Company's reportable segments        
Net Sales (11,799) (9,337) (22,189) (17,951)
Intersegment | Pharma        
Financial information regarding the Company's reportable segments        
Net Sales (154) (228) (502) (458)
Intersegment | Beauty        
Financial information regarding the Company's reportable segments        
Net Sales (9,972) (7,402) (18,495) (13,996)
Intersegment | Closures        
Financial information regarding the Company's reportable segments        
Net Sales (1,673) (1,707) (3,192) (3,497)
Corporate & Other        
Financial information regarding the Company's reportable segments        
Adjusted EBITDA (15,909) (17,378) (37,386) (40,889)
Restructuring Initiatives 19 5 488 (100)
Depreciation and amortization $ (1,104) $ (813) $ (2,239) $ (1,675)